The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of midostaurin and azacitidine in relapsed and elderly AML.
Brenda W. Cooper
Research Funding - Celgene; Novartis
Tamila L. Kindwall-Keller
No relevant relationships to disclose
Hillard M. Lazarus
No relevant relationships to disclose
Mehdi Hamadani
No relevant relationships to disclose
William W. Tse
No relevant relationships to disclose
Soumit K. Basu
No relevant relationships to disclose
Michael Craig
No relevant relationships to disclose